XBI holdings (2026)
All 148 positions in SPDR S&P Biotech ETF, ranked by portfolio weight — led by RVMD at 2.2%. Weights come from the fund's own SEC N-PORT filing and update daily with prices; positions in stocks ChartRow doesn't track still appear, ranked by weight, without returns. Not investment advice.
Weights are the Mar 31, 2026 SEC filing rolled forward on each holding's price move (as of market close, Aug 13, 2026) — an estimate of today, not the filed figure. Switch the table below to see them exactly as filed.
Top 10 holdings#
Sector weights#
XBI holdings by weight#
101–148 of 148| # | Company | Weight | Price | 1D | YTD | 1Y | Mkt cap |
|---|---|---|---|---|---|---|---|
| 101 | Geron Corp | 0.32% | — | — | — | — | — |
| 102 | Day One Biopharmaceuticals Inc | 0.31% | — | — | — | — | — |
| 103 | Precigen Inc | 0.30% | — | — | — | — | — |
| 104 | Vir Biotechnology Inc | 0.29% | — | — | — | — | — |
| 105 | KalVista Pharmaceuticals Inc | 0.28% | — | — | — | — | — |
| 106 | CytomX Therapeutics Inc | 0.27% | — | — | — | — | — |
| 107 | Annexon Inc | 0.27% | — | — | — | — | — |
| 108 | Kura Oncology Inc | 0.26% | — | — | — | — | — |
| 109 | Inhibrx Biosciences Inc | 0.26% | — | — | — | — | — |
| 110 | SELLAS Life Sciences Group Inc | 0.25% | — | — | — | — | — |
| 111 | Janux Therapeutics Inc | 0.25% | — | — | — | — | — |
| 112 | Compass Therapeutics Inc | 0.25% | — | — | — | — | — |
| 113 | Savara Inc | 0.25% | — | — | — | — | — |
| 114 | Rigel Pharmaceuticals Inc | 0.25% | — | — | — | — | — |
| 115 | Sana Biotechnology Inc | 0.25% | — | — | — | — | — |
| 116 | Cullinan Therapeutics Inc | 0.24% | — | — | — | — | — |
| 117 | ARS Pharmaceuticals Inc | 0.23% | — | — | — | — | — |
| 118 | Zenas Biopharma Inc | 0.23% | — | — | — | — | — |
| 119 | Xencor Inc | 0.22% | — | — | — | — | — |
| 120 | Replimune Group Inc | 0.22% | — | — | — | — | — |
| 121 | Sionna Therapeutics Inc | 0.21% | — | — | — | — | — |
| 122 | Vor BioPharma Inc | 0.21% | — | — | — | — | — |
| 123 | ArriVent Biopharma Inc | 0.21% | — | — | — | — | — |
| 124 | Ironwood Pharmaceuticals Inc | 0.18% | — | — | — | — | — |
| 125 | Bicara Therapeutics Inc | 0.18% | — | — | — | — | — |
| 126 | Prime Medicine Inc | 0.18% | — | — | — | — | — |
| 127 | Altimmune Inc | 0.17% | — | — | — | — | — |
| 128 | Absci Corp | 0.17% | — | — | — | — | — |
| 129 | Emergent BioSolutions Inc | 0.17% | — | — | — | — | — |
| 130 | Allogene Therapeutics Inc | 0.16% | — | — | — | — | — |
| 131 | Hyperliquid Strategies Inc | 0.16% | — | — | — | — | — |
| 132 | 4D Molecular Therapeutics Inc | 0.16% | — | — | — | — | — |
| 133 | Vanda Pharmaceuticals Inc | 0.15% | — | — | — | — | — |
| 134 | REGENXBIO Inc | 0.15% | — | — | — | — | — |
| 135 | Lexeo Therapeutics Inc | 0.14% | — | — | — | — | — |
| 136 | Verastem Inc | 0.14% | — | — | — | — | — |
| 137 | Arbutus Biopharma Corp | 0.13% | — | — | — | — | — |
| 138 | Myriad Genetics Inc | 0.12% | — | — | — | — | — |
| 139 | Prothena Corp PLC | 0.12% | — | — | — | — | — |
| 140 | Ocugen Inc | 0.12% | — | — | — | — | — |
| 141 | Rocket Pharmaceuticals Inc | 0.12% | — | — | — | — | — |
| 142 | MiMedx Group Inc | 0.12% | — | — | — | — | — |
| 143 | Akebia Therapeutics Inc | 0.11% | — | — | — | — | — |
| 144 | Anavex Life Sciences Corp | 0.10% | — | — | — | — | — |
| 145 | Invivyd Inc | 0.09% | — | — | — | — | — |
| 146 | Perspective Therapeutics Inc | 0.09% | — | — | — | — | — |
| 147 | Damora Therapeutics Inc | 0.03% | — | — | — | — | — |
| 148 | OMNIAB INC | 0.00% | — | — | — | — | — |
Methodology#
Holdings and weights are sourced from the fund's portfolio as disclosed to the SEC on Form N-PORT — a public filing. Portfolio filings are quarterly (public ~60 days after quarter end), so we anchor on the latest one and roll each weight forward daily by that holding's price move, keeping the numbers current between filings; positions in stocks ChartRow doesn't track carry their filed weight unchanged and show "—" where we have no data. Returns are total returns (dividends reinvested). One row per company, not per ticker: when a fund holds more than one share class of the same company (Alphabet's GOOGL and GOOG, for example), we combine them into a single row whose weight is the sum of its classes. Past performance does not predict future returns; not investment advice.
FAQ#
- What are the top 10 holdings of XBI?
- XBI's top 10 holdings are Revolution Medicines Inc. (RVMD), 2.2%; Apogee Therapeutics Inc. (APGE), 2.0%; Apellis Pharmaceuticals Inc, 1.7%; Natera Inc. (NTRA), 1.7%; Halozyme Therapeutics Inc. (HALO), 1.6%; Arrowhead Pharmaceuticals Inc. (ARWR), 1.6%; Alkermes PLC, 1.4%; Incyte Corp. (INCY), 1.4%; Praxis Precision Medicines Inc. (PRAX), 1.3%; Roivant Sciences Ltd. (ROIV), 1.3% — together about 16% of the fund, per its Mar 31, 2026 SEC filing with weights rolled forward to today.
- How many holdings does XBI have?
- SPDR S&P Biotech ETF (XBI) held 148 positions as of its latest SEC N-PORT filing (Mar 31, 2026).
- How current are XBI's holdings?
- Funds disclose their full portfolio to the SEC on Form N-PORT; the quarter-end report becomes public about 60 days later. ChartRow anchors on the latest public filing (Mar 31, 2026) and rolls each weight forward daily by that holding's price move, so the weights shown estimate today rather than the filing date.
- Is ChartRow affiliated with XBI or State Street?
- No. ChartRow is independent and is not affiliated with, sponsored by, or endorsed by State Street or SPDR S&P Biotech ETF. Everything on this page is derived independently from the fund's public SEC filings; fund names and trademarks belong to their owners. For information only — not investment advice.